Age is the single largest risk factor for human disease. One possible explanation for this correlation is that basic mechanisms that drive aging might also promote age-related diseases. If true, drugs that interfere with such mechanisms could treat numerous human ailments. Cellular senescence, an irreversible state of cell cycle arrest induced by cellular stresses, has emerged as a fundamental aging mechanism that also contributes to diseases of late life. The development of therapeutics that safely interfere with the damaging effects of cellular senescence is an exciting new area of pharmaceutical research with several recently developed drugs entering the phase of human clinical trials.
Jan van Deursen, received his Ph.D. degree in Cell Biology at the University of Nijmegen, Netherlands in 1993. He joined the staff of Mayo Clinic in 1999, where he directs a curiosity-driven research program focused on the basic biology of cancer and aging. He also directs of the transgenic and gene knockout core facility, the senescence program of the Robert and Arlene Kogod Center on Aging, the cell biology program of the comprehensive cancer center, the cancer and cell aging platform of the center for biomedical discovery, and the Paul Glenn laboratories of senescence. He is also chair of the Department of Biochemistry and Molecular Biology. Dr. van Deursen employs integrated genetic, genomic, cell biological and biochemical approaches to address fundamental questions regarding the biology of cancer and aging. The lab’s primary focus is on long-standing gaps in basic knowledge that have the potential to yield unexpected findings of high impact.
Host: A/Prof. Philipp Kaldis
Seminar is open to public, registration is not required.